Clostridioides difficile, formerly known as Clostridium difficile, is a bacterium notorious for causing severe gastrointestinal infections, often in healthcare settings. This resilient pathogen thrives in environments altered by antibiotic use, disrupting the balance of gut microbiota and allowing C. difficile to proliferate and produce toxins. The resulting infection, known as C. difficile-associated disease (CDAD), manifests as diarrhea, abdominal pain, and, in severe cases, life-threatening complications such as pseudomembranous colitis and toxic megacolon. Managing CDAD poses significant challenges due to the bacterium's ability to form resilient spores, making it resistant to many standard disinfection methods. Prevention and control strategies, including stringent hand hygiene practices, judicious antibiotic use, and environmental decontamination, are essential for combating C. difficile infections and reducing their impact on patient outcomes and healthcare systems.
Title : Diagnostic approaches, predictive and prognostic assessments, monitoring, treatment & management of infectious diseases and disease prevention
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Climate change & increasing pollution and respiratory illnesses
Yazdan Mirzanejad, University of British Columbia, Canada
Title : Climate change & increasing tickborne illnesses
Yazdan Mirzanejad, University of British Columbia, Canada
Title : The accelerated timeline: Human ecology, climate change, and the next global outbreak
Claudia Ferreira, Sorbonne University, France
Title : Invasive group A streptococcal infections in children: Current therapeutic challenges
Elena Chiappini, University of Florence, Italy
Title : Trends of treatment and vaccines for influenza, COVID-19, and pneumococcal diseases
Masafumi Seki, Saitama Medical University International Medical Center, Japan